Janus Henderson Group PLC Increases Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

Janus Henderson Group PLC grew its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 23.1% in the third quarter, according to its most recent filing with the SEC. The fund owned 10,921,896 shares of the company’s stock after acquiring an additional 2,052,989 shares during the quarter. Vaxcyte comprises approximately 0.6% of Janus Henderson Group PLC’s holdings, making the stock its 21st largest holding. Janus Henderson Group PLC owned 8.76% of Vaxcyte worth $1,247,954,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Riverview Trust Co purchased a new position in shares of Vaxcyte in the third quarter worth about $27,000. Blue Trust Inc. boosted its position in Vaxcyte by 33.5% during the third quarter. Blue Trust Inc. now owns 371 shares of the company’s stock worth $42,000 after acquiring an additional 93 shares during the last quarter. Fifth Third Bancorp acquired a new position in shares of Vaxcyte in the 2nd quarter worth $35,000. J.Safra Asset Management Corp lifted its stake in shares of Vaxcyte by 649.4% in the second quarter. J.Safra Asset Management Corp now owns 607 shares of the company’s stock worth $46,000 after buying an additional 526 shares during the last quarter. Finally, Meeder Asset Management Inc. increased its position in shares of Vaxcyte by 1,007.9% during the third quarter. Meeder Asset Management Inc. now owns 698 shares of the company’s stock valued at $80,000 after purchasing an additional 635 shares during the period. 96.78% of the stock is currently owned by hedge funds and other institutional investors.

Vaxcyte Price Performance

Shares of NASDAQ:PCVX opened at $91.60 on Tuesday. The company has a 50 day moving average of $105.60 and a 200-day moving average of $90.49. The stock has a market cap of $11.42 billion, a price-to-earnings ratio of -19.91 and a beta of 0.94. Vaxcyte, Inc. has a one year low of $52.74 and a one year high of $121.06.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.10) by $0.27. During the same quarter in the prior year, the business earned ($0.91) earnings per share. Equities research analysts anticipate that Vaxcyte, Inc. will post -4.14 earnings per share for the current year.

Wall Street Analyst Weigh In

PCVX has been the topic of a number of research reports. Mizuho lifted their price target on shares of Vaxcyte from $113.00 to $163.00 and gave the company an “outperform” rating in a research note on Tuesday, September 10th. Needham & Company LLC reissued a “buy” rating and set a $140.00 price target on shares of Vaxcyte in a research report on Wednesday, November 6th. BTIG Research raised their price target on Vaxcyte from $98.00 to $160.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Jefferies Financial Group lifted their price objective on Vaxcyte from $108.00 to $129.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Finally, Bank of America increased their target price on shares of Vaxcyte from $101.00 to $140.00 and gave the stock a “buy” rating in a report on Wednesday, September 4th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Vaxcyte presently has an average rating of “Buy” and an average price target of $147.50.

Insiders Place Their Bets

In other Vaxcyte news, CFO Andrew Guggenhime sold 8,000 shares of the company’s stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $115.94, for a total value of $927,520.00. Following the completion of the transaction, the chief financial officer now directly owns 90,383 shares of the company’s stock, valued at $10,479,005.02. This represents a 8.13 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Grant Pickering sold 2,366 shares of the stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $103.89, for a total value of $245,803.74. Following the transaction, the chief executive officer now directly owns 137,398 shares of the company’s stock, valued at approximately $14,274,278.22. The trade was a 1.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 87,464 shares of company stock valued at $9,797,926 over the last 90 days. Insiders own 3.10% of the company’s stock.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.